Baidu
map

Onco Targets Ther:贝伐单抗+紫杉醇联合治疗对HER2-乳腺癌患者安全有效

2014-12-09 MedSci译 MedSci原创

OncoTargets and Therapy:接受贝伐单抗+紫杉醇联合治疗HER2(-)乳腺癌患者安全有效 研究背景:抗血管生成药物贝伐单抗与细胞毒化疗药物联合运用(较细胞毒单药)作为HER2(-)转移性乳腺癌的一线治疗经一系列临床试验证实明显延长患者无病进展期(PFS),然而并没有将此种联合运用于后续治疗的报道。 研究目的:本研究拟讨论HER2(-)转移性乳腺癌运用贝伐单抗+紫杉醇联合

研究背景:抗血管生成药物贝伐单抗与细胞毒化疗药物联合运用(较细胞毒单药)作为HER2(-)转移性乳腺癌的一线治疗经一系列临床试验证实明显延长患者无病进展期(PFS),然而并没有将此种联合运用于后续治疗的报道。 研究目的:本研究拟讨论HER2(-)转移性乳腺癌运用贝伐单抗+紫杉醇联合作为一线和后续治疗的效果及安全性。研究方法:回顾性分析2007年8月-2012年10月西班牙马德里和平医院的接受贝伐单抗(10mg/kg第1、15天,28日疗法)+紫杉醇(80mg/㎡ 第1、8、15天,28日疗法)的HER2(-)转移性乳腺癌患者,每3月进行一次随访以评价疗效。收集患者的临床病理信息,运用SPSS软件进行统计学分析。研究结果:共纳入78名患者,患者基本特征见Table1,大部分患者雌激素受体(ER)阳性、浸润性导管癌占83.3%,大部分患者(75.6%)无瘤间期(DFI)>24个月。43(51.1%)名患者接受贝伐单抗+紫杉醇一线治疗,45(57.7%)患者接受后续贝伐单抗持续治疗,其中40(88.9%)名患者ER(+),20(44.4%)名患者接受内分泌治疗+贝伐单抗后续治疗。 治疗效果见

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1982499, encodeId=8848198249979, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 03 13:20:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045121, encodeId=af46204512109, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 04 03:20:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795311, encodeId=80001e95311bb, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 11 13:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14310, encodeId=0bec14310e2, content=v 机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 14 14:59:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13649, encodeId=5c1e136495e, content=读完之后收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65bb108976, createdName=yigao324, createdTime=Thu Jan 01 20:11:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313629, encodeId=5dc2131362989, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476955, encodeId=13c814e69559c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570937, encodeId=cbec15e09375a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
    2015-06-03 luwei00
  2. [GetPortalCommentsPageByObjectIdResponse(id=1982499, encodeId=8848198249979, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 03 13:20:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045121, encodeId=af46204512109, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 04 03:20:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795311, encodeId=80001e95311bb, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 11 13:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14310, encodeId=0bec14310e2, content=v 机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 14 14:59:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13649, encodeId=5c1e136495e, content=读完之后收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65bb108976, createdName=yigao324, createdTime=Thu Jan 01 20:11:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313629, encodeId=5dc2131362989, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476955, encodeId=13c814e69559c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570937, encodeId=cbec15e09375a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1982499, encodeId=8848198249979, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 03 13:20:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045121, encodeId=af46204512109, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 04 03:20:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795311, encodeId=80001e95311bb, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 11 13:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14310, encodeId=0bec14310e2, content=v 机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 14 14:59:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13649, encodeId=5c1e136495e, content=读完之后收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65bb108976, createdName=yigao324, createdTime=Thu Jan 01 20:11:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313629, encodeId=5dc2131362989, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476955, encodeId=13c814e69559c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570937, encodeId=cbec15e09375a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
    2014-12-11 闆锋旦
  4. [GetPortalCommentsPageByObjectIdResponse(id=1982499, encodeId=8848198249979, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 03 13:20:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045121, encodeId=af46204512109, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 04 03:20:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795311, encodeId=80001e95311bb, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 11 13:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14310, encodeId=0bec14310e2, content=v 机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 14 14:59:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13649, encodeId=5c1e136495e, content=读完之后收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65bb108976, createdName=yigao324, createdTime=Thu Jan 01 20:11:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313629, encodeId=5dc2131362989, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476955, encodeId=13c814e69559c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570937, encodeId=cbec15e09375a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
    2015-01-14 loveios

    v 机会

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1982499, encodeId=8848198249979, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 03 13:20:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045121, encodeId=af46204512109, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 04 03:20:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795311, encodeId=80001e95311bb, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 11 13:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14310, encodeId=0bec14310e2, content=v 机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 14 14:59:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13649, encodeId=5c1e136495e, content=读完之后收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65bb108976, createdName=yigao324, createdTime=Thu Jan 01 20:11:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313629, encodeId=5dc2131362989, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476955, encodeId=13c814e69559c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570937, encodeId=cbec15e09375a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
    2015-01-01 yigao324

    读完之后收获很多

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1982499, encodeId=8848198249979, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 03 13:20:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045121, encodeId=af46204512109, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 04 03:20:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795311, encodeId=80001e95311bb, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 11 13:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14310, encodeId=0bec14310e2, content=v 机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 14 14:59:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13649, encodeId=5c1e136495e, content=读完之后收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65bb108976, createdName=yigao324, createdTime=Thu Jan 01 20:11:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313629, encodeId=5dc2131362989, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476955, encodeId=13c814e69559c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570937, encodeId=cbec15e09375a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1982499, encodeId=8848198249979, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 03 13:20:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045121, encodeId=af46204512109, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 04 03:20:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795311, encodeId=80001e95311bb, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 11 13:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14310, encodeId=0bec14310e2, content=v 机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 14 14:59:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13649, encodeId=5c1e136495e, content=读完之后收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65bb108976, createdName=yigao324, createdTime=Thu Jan 01 20:11:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313629, encodeId=5dc2131362989, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476955, encodeId=13c814e69559c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570937, encodeId=cbec15e09375a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1982499, encodeId=8848198249979, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 03 13:20:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045121, encodeId=af46204512109, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 04 03:20:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795311, encodeId=80001e95311bb, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 11 13:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14310, encodeId=0bec14310e2, content=v 机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 14 14:59:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13649, encodeId=5c1e136495e, content=读完之后收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65bb108976, createdName=yigao324, createdTime=Thu Jan 01 20:11:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313629, encodeId=5dc2131362989, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476955, encodeId=13c814e69559c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570937, encodeId=cbec15e09375a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 11 12:20:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]

相关资讯

Clin Cancer Res:乳腺癌疫苗?临床试验现曙光

早期的临床试验结果指出,由圣路易斯的华盛顿大学医学院研发的乳腺癌疫苗在转移性乳腺癌患者中具有相当的安全性。初步的证据也表明,疫苗能够激发患者的免疫系统对肿瘤细胞进行攻击,有助于延缓癌症的进展。该研究发表在12月1日的Clinical Cancer Research杂志上。这种新的疫苗会导致人体的免疫系统追踪一种叫做Mammaglobin-A的蛋白,而这种蛋白几乎只在乳腺组织中存在。这种蛋白在健康组

Med Oncol:乳腺癌脑转移的风险及预后评估

Med Oncol:乳腺癌脑转移的风险及预后评估 研究背景:乳腺癌一旦发生脑转移对于医生和患者来说是一个巨大挑战,脑转移患者有更差的预后,初诊后2年之内是发生脑转移的高峰期,已知的脑转移危险因素包括较小的年龄、低分化肿瘤、雌激素受体(ER)阴性或三阴性乳腺癌(TNBC)、HER2阳性。 研究目的:本文拟研究乳腺癌发生中枢神经系统(CNS)转移的危险因素以及脑转移后预后差异。 研究方案:纳入人

Circulation:乳腺癌患者预防心血管事件的ABCDE五条建议

Circulation:乳腺癌患者预防心血管事件的ABCDE五条建议 随着诊断及治疗的进步、乳腺癌的存活得到了很大改善,但是乳腺癌患者将会面临很多挑战,导致乳腺癌死因的头号杀手是心脏问题,乳腺癌患者采取什么措施来减轻其心脏病风险?哈佛大学研究者们告诉你。 心脏的供血有赖于冠状动脉,一旦阻塞导致冠心病(CAD),使心肌不能获得足够营养和氧气,CAD随着危险因素的暴露而进展,这些危险因素包括高

Am J Pathol:预测三阴性乳腺癌疾病结果的生物标记物

“三阴性”乳腺癌(TNBC)患者的癌细胞不表达雌激素受体,孕激素受体和/或人类表皮生长因子受体2。由于缺少预测生物标记,“三阴性”乳腺癌的治疗方法是很困难选择的。 现在,研究人员报告说,肿瘤微环境中的高水平miR-21,而不是在上皮癌细胞中的miR-21与三阴乳腺癌患者更差的临床结果相关联,从而识别三阴乳腺癌的一个潜在预后生物标志物,研究发表于The American Journal of P

Radiology:乳腺癌Luminal B分子亚型在MR图像显示出病灶增强

基因组分析可将乳腺癌分为四个分子亚型,luminal(腔内)A 型、luminal (腔内)B 型、基底样型及 HER-2 过表达型。这些亚型的分布与种族、绝经状况以及年龄有关,不同分子亚型对治疗反应的差异可以指导临床制定初始治疗计划。如果不进行传统基因组学分析,而能从影像学检查中获取分子亚型的相关信息,这无疑将对乳腺癌的诊断产生巨大意义。来自美国杜克大学的 Mazurowski 教授等

JCO:三阴性乳腺癌治疗的新靶标

新加坡A * STAR基因组研究所(GIS)科学家与当地临床医生和美国同事合作,确定了一种与三阴性乳腺癌(TNBC)相关的生物标志物。新发现的生物标记物称为RASAL2基因,RASAL2基因或是治疗这种致命疾病的新靶标。 三阴乳腺癌是致命,因为其不同于其他类型的乳腺癌如雌激素受体(ER)阳性乳腺癌,靶向疗法能有效治疗ER阳性乳腺癌,但三阴乳腺癌肿瘤对靶向治疗无反应。 乳腺癌有许多亚型,每种类型

Baidu
map
Baidu
map
Baidu
map